Objective: In this study our main goal is to evaluate the effect of dyslipidemia Associated with Hypertension for Coronary Heart Disease.

Method: This case control type of study was conducted in Cardiology Department of National Institute of Cardiovascular Diseases (NICVD), during January 2018 until December 2019. Study subjects were selected from admitted patient with acute coronary syndrome at emergency department and at in-patient department of the Cardiology Department.

Results: During the study, in case group dyslipidemia and hypertension were present in 77% and 62.5% patients. Where as in control group it was 30% and 20%. In cas group mean± SD of systolic blood pressure was found 134.75± 19.25 and random blood sugar was found in 223.81 ± 72.18 mg/dl. In full model of dyslipidemia with CHD interaction between dyslipidemia and hypertension were found as confounder.

Conclusion: From our study, it is concluded that dyslipidemia and hypertension are established risk factors of prime importance in CHD development. Relationship of dyslipidemia with coronary heart disease in hypertension is significant. Additional research, in particular longitudinal studies, is needed to explore the complex interaction of these factors and to inform policies and programs for the inhibition and supervision of CHDs in Bangladesh.

Keywords: Coronary heart disease (CHD), dyslipidemia, hyperlipidemias.

1. Pahor M, Shorr RI, Somes GW. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 1998;158:1340-5.
2. Kim MC, Kini AS, FusterV.Definitions of acute coronary syndromes:Non-ST elevation myocardial infarction.In: Fuster V, O’Rourke RA,Walsh RA, Poole-Wilson P.Eds. Hurst’s the Heart. 12^th New York, USA: McGraw Hill; 2008.1314.
3. Berger CJ, Murabito JM, Evam JC. Prognosis after first myocardial infarction: comparison of Q-wave and Non Q-wave myocardial infarction in the framingham–heart study. JAMA 1992; 268: 1545-46.
4. Cooper H, Panza JA. Q wave to guide treatment of myocardial infarction.Lancet 2006 24(367):2035-2037.
5. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update, CMAJ. 2003 October 28: 169(9): 921-924.
6. Antman EM, Braunwald E.ST-elevation myocardial infarction. In: Libby P,Bonow RO, Mann DL, Zipes DP. Eds. Braunwald’s heart disease. 8^th Philadelphia, USA: Saunders; 2008. 1221-1222.
7. Ariyanti R and Besral B, Dyslipidemia Associated with Hypertension Increases the Risks for Coronary Heart Disease: A Case-Control Study in Harapan Kita Hospital, National Cardiovascular Center, Jakarta, Journal of Lipids Volume 2019, Article ID 2517013, 6 pageshttps://doi.or/101155/2019/2517013.
8. Bashore TM, Granger CB, Hranitzky P, Patel MR. Coronary heart disease. In: McPhee S, Papakadias MA. Eds. Current medical diagnosis and treatment. 49^th New York, USA: McGraw Hill; 2010; 317.
9. H. Nelson, “Hyperlipidemia as a risk factor for cardiovascular disease,” Primary Care: Clinics in Office Practive, vol, 40, no. 10,pp. 195-211, 201. View at: Publisher site Google Scholar.
10. -F. Lin, Y.-H. Chang, S.C. Chien, Y.-H. Lin, and H.-Y. Yeh. “Epidemiology of dyslipidemia in the asia pacific region,” International Journal of Gerontology, vol. 12, no. 1, pp. 2-6, 2018.View at: Publisher site Google Scholar.
11. Perkumpulan Endokrinologi Indonesia (PERKENI), Konsensus Pengelolaan Dislipidemia di Indonesia, Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran UI, 2015.

Lieutenant Colonel Dr Md. Fakhrul Alam

BSP, MPH, Commanding Officer, 11 Field Ambulance, Savar Cantonment, Bangladesh